Safety Protocols
Evidence-based safety protocols for medicinal leech therapy: patient selection, infection control, bleeding management, and institutional implementation.
Safety Framework
1. Patient Selection Criteria
1.1 Inclusion Criteria
- Venous Congestion: Tissue congestion from venous insufficiency, replantation surgery, or trauma
- Failed Conventional Therapy: Patients who have not responded to standard treatments
- Informed Consent: Patient understands risks (infection, bleeding, scarring) and benefits
- Adequate Support: Ability to monitor and manage post-treatment bleeding (24-72 hours)
1.2 Absolute Contraindications
- Coagulopathy: Hemophilia, von Willebrand disease, or other bleeding disorders
- Anticoagulation: Current use of warfarin, heparin, or DOACs (must be discontinued before treatment)
- Septicemia: Active systemic infection
- Severe Anemia: Hemoglobin < 8 g/dL without transfusion support
- Immunocompromise: AIDS, active chemotherapy, or immunosuppressive therapy (without adequate antibiotic prophylaxis)
1.3 Relative Contraindications
- Aspirin/NSAIDs: Increased bleeding duration (discuss withholding 7-10 days)
- Diabetes: Increased infection risk (requires prophylactic antibiotics)
- Pregnancy: Inadequate safety data (avoid unless no alternatives)
- Pediatric Patients: Limited evidence; requires close monitoring
- Elderly Patients (>65 years): Polypharmacy review required (anticoagulants, antiplatelets, NSAIDs). Reduced blood volume tolerance — lower transfusion threshold (Hgb <8 g/dL with CAD). Renal dose adjustment for fluoroquinolone prophylaxis (CrCl-based). Extended post-procedure observation. See Clinical Protocols for detailed geriatric considerations.
2. Infection Control
2.1 Aeromonas Infection Risk
Aeromonas spp. are commensal bacteria in the leech digestive tract that can rarely cause infection (1.3-9.7% incidence). Most infections are mild and localized; severe disseminated infections are extremely rare.
2.2 Antibiotic Protocols
Prophylactic Regimens
First-Line Prophylaxis:
- Ciprofloxacin: 500 mg PO BID — initiate before first leech application, continue for the entire duration of leech therapy plus 24 hours after the last leech is removed. Extended courses (up to 7-14 days total) may be considered in immunocompromised patients or when wound healing is delayed
- Trimethoprim-sulfamethoxazole: 800/160 mg PO BID — initiate before first leech application, continue for the entire duration of leech therapy plus 24 hours after the last leech is removed. Extended courses (up to 7-14 days total) may be considered in immunocompromised patients or when wound healing is delayed
Alternative Regimens:
- Amoxicillin-clavulanate: 875/125 mg PO BID
- Doxycycline: 100 mg PO BID
- Levofloxacin: 500 mg PO QD
Important
2.3 Infection Monitoring
- Clinical Signs: Monitor for erythema, warmth, swelling, purulent drainage, or foul odor (48-96 hours post-treatment)
- Systemic Signs: Fever, chills, leukocytosis (if present, check WBC)
- Early Intervention: If infection suspected, obtain wound culture and start empiric antibiotics immediately
3. Bleeding Management
3.1 Expected Bleeding
Post-leech bleeding is expected and normal due to anticoagulant salivary compounds. Typical bleeding duration: 4 to 24 hours (occasionally longer). Patients should be counseled that this is part of the therapeutic process.
3.2 Patient Education
Pre-Treatment Counseling
- Bleeding is expected and will last 4 to 24 hours
- Expect to use 10-15 absorbent pads per 24 hours
- Avoid vigorous activity, heavy lifting, or straining
- Keep affected area elevated when possible
- Seek care if bleeding is excessive or if signs of infection develop
3.3 Bleeding Control Techniques
Stepwise Approach
- First-Line (Routine):
- Apply absorbent dressings (change every 4-8 hours)
- Elevate affected area
- Avoid disrupting clot formation
- Second-Line (Persistent Bleeding):
- Thrombin powder or gelatin sponge
- Pressure dressing (avoid excessive pressure)
- Silver nitrate stick (cautiously; can cause tissue damage)
- Third-Line (Refractory Bleeding):
- Topical hemostatic agents (FlowSeal AH, SurgiCel)
- Suture ligation (ultimate resort)
- Consider transfusion if hemoglobin drops significantly
Warning
4. Adverse Event Management
4.1 Common Adverse Events
Local Reactions
- Pain/Discomfort: Typically mild; manage with acetaminophen
- Erythema/Edema: Expected; resolves in 48-72 hours
- Scarring: Minimal if proper technique used
- Itching: Topical antihistamines; avoid scratching
Systemic Reactions
- Allergic Reactions: Rare; treat per standard protocols
- Anemia: Monitor CBC if heavy bleeding
- Infection: See Section 2 (above)
- Vasovagal Response: Extremely rare; supportive care
4.2 Emergency Management
Seek Immediate Care If:
- Uncontrolled bleeding despite conservative measures
- Signs of hemorrhagic shock (hypotension, tachycardia, altered mentation)
- Severe allergic reaction (anaphylaxis)
- Signs of systemic infection (fever, rigors, hypotension)
- Severe anemia (Hb < 7 g/dL)
5. Institutional Implementation
5.1 Protocol Development
Institutions should develop written protocols covering patient selection, treatment procedures, post-procedure care, and complication management. Protocols should be:
- Evidence-based and regularly updated
- Approved by institutional review board (IRB) or pharmacy & therapeutics committee
- Accessible to all staff involved in leech therapy
- Regularly audited for compliance
5.2 Staff Training
All personnel involved in leech therapy should receive training on:
- Leech biology and mechanism of action
- Application techniques and best practices
- Patient selection criteria and contraindications
- Infection control and antibiotic protocols
- Bleeding management and patient education
- Emergency protocols and when to escalate care
5.3 Quality Assurance
- Track Outcomes: Maintain registry of all leech therapy cases
- Monitor Complications: Track infection and bleeding rates
- Regular Review: Periodic audit of protocol adherence
- Continuous Improvement: Update protocols based on new evidence
Clinical Bottom Line
Medicinal leech therapy can be safely administered when proper safety protocols are followed. Key elements include: (1) careful patient selection and screening for contraindications, (2) routine prophylactic antibiotics (ciprofloxacin or TMP-SMX), (3) patient education on expected bleeding and warning signs, (4) systematic bleeding management algorithms, and (5) institutional protocols with staff training and quality assurance monitoring.
Related Research
Nosocomial Infections from Medicinal Leeches — Epidemiology and Prevention
Systematic investigation of nosocomial infections caused by Aeromonas species following medicinal leech therapy. Characterized the clinical presentation, microbiological profile, and risk factors for infection, establishing the evidence base for routine antibiotic prophylaxis during leech therapy.
Sartor C et al. · Clinical Infectious Diseases
Safety Profile of Medicinal Leech Therapy
Comprehensive safety review covering Aeromonas hydrophila infection (15–30% without prophylaxis, 2–5% with), bleeding management (40–80 mL/day), absolute and relative contraindications, and the 2025 ciprofloxacin-resistance alert. Standard prophylaxis protocols and monitoring requirements for clinical practice.
ASH Evidence Compendium · ASH Clinical Reference
Analysis of antibiotic resistant infections associated with hirudotherapy
Given rising concern regarding antibiotic resistance, our objective was to evaluate antibiotic-resistant infections following leech therapy and to characterize the use of prophylactic antibiotics.
Brauer P et al. · American journal of otolaryngology
Improvement of patient care through hirudotherapy and the management of leeches from their reception to their disposal in France
Medicinal leech therapy - known as hirudotherapy (HT) - is an empirical medical technique that has become popular again in reconstructive surgery. However, at each step of leech management there are risks for blood contamination of the caregivers and severe infections for patients.
Vaesken C et al. · European journal of hospital pharmacy : science and practice
Leech Application-related Upper Gastrointestinal Bleeding: A Case Report
Leech therapy (Hirudotherapy) is a method used in the treatment of many diseases since ancient times. Although many complications have been reported following the use of this method, no systemic life-threatening bleeding has yet been described.
Dolek U et al. · Bulletin of emergency and trauma
Rethinking antimicrobial prophylaxis in patients receiving medicinal leech therapy
To describe challenges in the management of prophylaxis against infections for patients receiving medicinal leech therapy given changes in antimicrobial resistance patterns in the normal flora of leeches.
McCracken J, Koehler S, Sharma R · American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Related Resources
Clinical Evidence
Review evidence across 7 conditions including osteoarthritis, venous insufficiency, and more.
Learn more →
Clinical Applications
Tier-organized applications from FDA-cleared indications to investigational uses.
Learn more →
What Is Hirudotherapy
Mechanism of action, bioactive compounds, and physiological effects.
Learn more →
Microbiome
The bacterial community of medicinal leeches.
Learn more →
Contraindications & Patient Selection
Absolute and relative contraindications, drug interactions, and screening protocols.
Learn more →